Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study

Background. Liver inflammation influences monocyte function, recruitment, and consequently inflammatory and fibrogenic responses. We aimed to investigate changes in the circulating monocyte phenotypes in response to Daclatasvir-Sofosbuvir (SOF/DCV) therapy in chronic hepatitis C (CHC) and relate fin...

Full description

Bibliographic Details
Main Authors:	Hanan M. Fayed, Ali A. Ghweil, Mona M. AbdelMeguid
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	Interdisciplinary Perspectives on Infectious Diseases
Online Access:	http://dx.doi.org/10.1155/2019/9469567

Similar Items

Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
by: Andrew Hill, et al.
Published: (2016-01-01)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
by: Michael Duerr, et al.
Published: (2019-02-01)

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin
by: Saverio G. Parisi, et al.
Published: (2016-08-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS
by: S. V. Zhavoronok, et al.
Published: (2018-10-01)

TREATMENT OF HCV INFECTION BY A COMBINATION OF SOFOSBUVIR AND DACLATASVIR
by: Y. O. SHULPEKOVA, et al.
Published: (2017-05-01)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
by: Lucas Pereira Jorge de Medeiros, et al.
Published: (2018-04-01)

Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3
by: Muhammad Sarfraz, et al.
Published: (2018-12-01)

Restoration of natural killer cell activity in chronic hepatitis C-infected Egyptian patients treated by sofosbuvir/daclatasvir with or without ribavirin
by: Hamdy M Moustafa, et al.
Published: (2021-01-01)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
by: Sperl J, et al.
Published: (2017-06-01)

Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin
by: Mohamed DA Abd Alla, et al.
Published: (2018-01-01)

Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant
by: Lluís Castells, et al.
Published: (2017-01-01)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
by: M. Shabani, et al.
Published: (2021-07-01)

Response of Sofosbuvir and Daclatasvir combination in Chronic Hepatitis C with Hemodialysis Pakistani Patients: A Single Centre Study
by: Rahmat Ali Khan, et al.
Published: (2018-12-01)

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village
by: Ossama Ashraf Ahmed, et al.
Published: (2018-01-01)

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021-01-01)

Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
by: Pin-Nan Cheng, et al.
Published: (2019-05-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
by: Hassan AM, et al.
Published: (2018-06-01)

Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
by: Shafiq Ur Rehman Cheema, et al.
Published: (2019-11-01)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01)

Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study)
by: Omaima Mohamed Ali, et al.
Published: (2020-07-01)

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review
by: Marcos Mucenic, et al.
Published: (2019-02-01)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
by: Hassan AM, et al.
Published: (2019-05-01)

Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study
by: Raffaella Lionetti, et al.
Published: (2019-05-01)

Sofosbuvir and daclatasvir are safe and effective in treatment of recurrent hepatitis C virus in Egyptian patients underwent living donor liver transplantation
by: Osama Aboelfotoh Aly, et al.
Published: (2020-09-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Role of optical coherence tomography angiography in detecting possible retinal vascular complications of sofosbuvir and daclatasvir in patients with hepatitis C virus infection
by: Hany E Elmekkawy, et al.
Published: (2021-01-01)

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
by: Yun Lu, et al.
Published: (2018-01-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin
by: K.S. Abdelkawy, et al.
Published: (2020-01-01)

Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring
by: Ahmed Mohamed El Missiri, et al.
Published: (2020-07-01)

Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients
by: Muhammad Ikhlaq, et al.
Published: (2018-12-01)

Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.
by: Ahmed Nagaty, et al.
Published: (2017-01-01)

Daclatasvir: potential role in hepatitis C
by: Lee C
Published: (2013-10-01)

Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
by: Mostafa Yakoot, et al.
Published: (2017-07-01)

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
by: Harel Dahari, et al.
Published: (2016-05-01)

Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon
by: Andréa Monteiro Tarragô, et al.